<DOC>
	<DOCNO>NCT00879827</DOCNO>
	<brief_summary>The purpose study evaluate immune response reactogenicity GSK Biologicals ' DTPa-HBV-IPV combine pentavalent vaccine Hib tetanus conjugate vaccine , administer concomitantly three-dose primary vaccination course .</brief_summary>
	<brief_title>Immunogenicity Reactogenicity GSK Bio DTPa-HBV-IPV Hib Vaccines When Coadministered Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female infant 6 8 week age time first vaccination . Free obvious health problem establish medical history clinical examination enter study . Written inform consent obtain parent guardian subject . Born normal gestation period ( 36 42 week ) . Use investigational nonregistered drug vaccine study vaccine ( ) study period within 30 day precede first dose study vaccine . Administration chronic immunosuppressant immunemodifying drug since birth plan administration study . Planned administration/ administration vaccine foreseen study protocol period start 30 day dose vaccine ( ) end 30 day . Previous vaccination diphtheria , tetanus , pertussis , polio Haemophilus influenzae type b . History , intercurrent , diphtheria , tetanus , pertussis , hepatitis B , polio and/or Haemophilus influenzae type b . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus infection . Major congenital defect Serious chronic illness History allergic disease reaction likely exacerbate component vaccine . Administration immunoglobulins and/or blood product since birth plan administration study period . Acute disease time enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>8 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>